360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Protalix BioTherapeutics Inc

Type: Company

Name: Protalix BioTherapeutics Inc (Protalix Biotherapeutics Inc)

Fact Sheet: Fact Sheet for Protalix BioTherapeutics Inc

First reported 20 hours ago - Updated 20 hours ago - 1 reports

Protalix BioTherapeutics Earnings Review: 9 Days after Announcement Shares Down 1.9% (PLX)

(Financial News Network On) When Protalix BioTherapeutics (AMEX:PLX) reported earnings a week ago on May 9th, 2013, analysts, on average, expected the company to report a loss of $0.06 on sales of $5.7 million. The company actually reported a loss of ... [Published Individual.com - 20 hours ago]

Entities: Protalix BioTherapeutics Inc, Stocks

First reported May 08 2013 - Updated May 08 2013 - 3 reports

Tel Aviv Stock Exchange

Protalix Biotherapeutics, Inc. to Present at the Oppenheimer 14th Annual Israeli Conference

(GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the Oppenheimer 14th Annual Israeli Conference on Sunday, May 12, ... [Published BioSpace - May 08 2013]

Entities: Protalix BioTherapeutics Inc, David Aviezer, Tel Aviv Stock Exchange, Intercontinental Hotels Group Plc

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Investing Ideas: Biodefense Stocks to Watch

(Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biodefense stocks issues the following update of publicly traded companies in the sector ... [Published InvestorIdeas.com - May 03 2013]

Entities: Biological Defense, Vaccine, Recombinant, Infectious Diseases

First reported Apr 29 2013 - Updated Apr 29 2013 - 8 reports

Protalix Biotherapeutics, Inc. (PLX) Release: UPLYSO (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

Staying up-to-date has never been simpler. Sign up for the today! CARMIEL, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the Mexican Federal Commission for the Protection against ... [Published BioSpace - Apr 29 2013]

Entities: Gaucher's disease, Protalix BioTherapeutics Inc, Chile, Mexico

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Buyers Accumulate Shares of Protalix BioTherapeutics, Up 5.1%

(Financial News Network On) Protalix BioTherapeutics (AMEX:PLX), a company whose shares are moving quickly, is trading 5.1% higher to $5.79. The S&P is currently trading 0.8% higher to 1,595 and the Dow Jones Industrial Average is trading 0.7% higher ... [Published Individual.com - Apr 29 2013]

Entities: Protalix BioTherapeutics Inc, Stocks, Dow Jones Industrial Average

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Small Cap Stocks To Watch - CPTS, BWEN, FXEN, PLX

NASDAQ:CPTS / NASDAQ:FXEN04/29/2013 [ACCESSWIRE]Conceptus, Inc. (Nasdaq: CPTS) $25.90. Announced Today that Conceptus has signed a definitive merger agreement with Bayer HealthCare LLC, Leverkusen, Germany.With this acquisition, Bayer will be able to ... [Published BayStreet.ca - Apr 29 2013]

Entities: Conceptus Inc, Broadwind Energy Inc, FX Energy Inc

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

Filed: 2013-04-29 AccNo: 0001144204-13-024427 Size: 33 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits ... [Published SEC Filings - Apr 29 2013]

Entities: Protalix BioTherapeutics Inc, 8-k

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Protalix BioTherapeutics Rating Lowered to Underperform at Zacks (PLX)

Protalix BioTherapeutics (NYSE: PLX) traded down 0.54% on Monday, hitting $5.51. Protalix BioTherapeutics has a 1-year low of $4.71 and a 1-year high of $7.70. The stock's 50-day moving average is currently $5.59. The company's market cap is $506.9 m ... [Published American Banking News - Stock Ratings - Apr 22 2013]

Entities: Protalix BioTherapeutics Inc, Recombinant, Moving Average, Protein

First reported Apr 13 2013 - Updated Apr 13 2013 - 1 reports

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease

Category: Proteins and PeptidesHits: 144CARMIEL, Israel I April 2, 2013 I Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (PLX.TA), announced today that the first patient has been treated in the Company's phase I clinical trial of PRX-112, or Oral GCD, ... [Published PipelineReview - Apr 13 2013]

Entities: Protalix BioTherapeutics Inc, Enzyme, Gaucher's disease, Phase I

First reported Apr 02 2013 - Updated Apr 02 2013 - 1 reports

8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

Filed: 2013-04-02 AccNo: 0001144204-13-019478 Size: 28 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits ... [Published SEC Filings - Apr 02 2013]

Entities: Protalix BioTherapeutics Inc, 8-k

First reported Mar 19 2013 - Updated Mar 19 2013 - 1 reports

Pfizer, Protalix type I Gaucher disease drug Uplyso gets Brazilian approval

Pfizer and Protalix BioTherapeutics have obtained approval from the Brazilian National Health Surveillance Agency for Uplyso (alfataliglicerase) as type I Gaucher disease therapy. ... [Published PBR - News - Mar 19 2013]

Entities: Protalix BioTherapeutics Inc, Gaucher's disease, Pfizer Inc

First reported Dec 06 2012 - Updated Dec 07 2012 - 3 reports

Protalix inks clinical development agreement with Pfizer for Elelyso

Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins, has entered into a clinical development agreement with Pfizer Inc. under which Protalix will continue to ... [Published PharmaBiz - Dec 07 2012]

Entities: Protalix BioTherapeutics Inc, Elelyso, Pfizer Inc

Quotes

Protalix VP medical affairs Dr. Raul Chertkoff said, "Including Mexico and Chile, Uplyso has been reviewed and approved by six different regulatory authorities across the globe. Through our joint efforts with Pfizer, we are working on expanding the commercial potential for Uplyso in additional countries."

Protalix wins Mexican, Chilean approval for Gaucher drug [Published Globes - Apr 29 2013]

"We have not yet determined if the well is commercial," noted David Pierce, CEO, "but we are cautiously optimistic and therefore will run a liner to allow more thorough testing. We are also reviewing a range of possible follow-on actions, including other potential drilling locations, to appraise the scope and potential of this Ca1/Upper Devonian zone both nearby and right across our Edge concessions. We will have plans ready for a prompt response if the production test is encouraging."

Small Cap Stocks To Watch - CPTS, BWEN, FXEN, PLX [Published BayStreet.ca - Apr 29 2013]

"We are very happy that UPLYSO may now be made available as an additional treatment alternative to Gaucher patients in Mexico and Chile" stated Dr. Raul Chertkoff, the Company's Vice President, Medical Affairs...

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile . . . [Published Equities.com - Apr 29 2013]

...said Professor Ari Zimran, M D , Director of the Gaucher Clinic in Shaare Zedek Medical Center, Jerusalem, Israel and lead clinical investigator. "We believe oral delivery of GCD has the potential to improve patients' quality of life without compromising the efficacy or safety of the treatment."

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Ad ... [Published PipelineReview - Apr 13 2013]

More Content

sort by: Date \| Relevance
Protalix BioTherapeutics Earnings Review: 9 Day... [Published Individual.com - 20 hours ago]
Protalix Biotherapeutics, Inc. to Present at th... [Published BioSpace - May 08 2013]
Protalix BioTherapeutics to Present at the Oppe... [Published Morningstar.com - May 08 2013]
Protalix BioTherapeutics to Present at the Oppe... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Protalix BioTherapeutics to Present at the Oppe... [Published Street Insider - May 08 2013]
Investing Ideas: Biodefense Stocks to Watch [Published InvestorIdeas.com - May 03 2013]
Free Research Reports on GWAY, HNT, MDSO and PL... [Published StockHouse USA - Apr 30 2013]
Mon: Telcos fail to boost flat market [Published Globes - Apr 29 2013]
Protalix Biotherapeutics, Inc. (PLX) Release: U... [Published BioSpace - Apr 29 2013]
Buyers Accumulate Shares of Protalix BioTherape... [Published Individual.com - Apr 29 2013]
J.C. Penney Lands a Loan, Protalix Rides on App... [Published Wall St. Cheat Sheet - Apr 29 2013]
J.C. Penney Lands a Loan, Protalix Rides on App... [Published Wall St. Cheat Sheet - Apr 29 2013]
Protalix wins Mexican, Chilean approval for Gau... [Published Globes - Apr 29 2013]
Small Cap Stocks To Watch - CPTS, BWEN, FXEN, PLX [Published BayStreet.ca - Apr 29 2013]
Protalix BioTherapeutics Treatment for Gaucher ... [Published Capital.gr - Apr 29 2013]
UPLYSO(TM) (alfataliglicerase) Approved in Mexi... [Published Equities.com - Apr 29 2013]
8-K - Protalix BioTherapeutics, Inc. (000100628... [Published SEC Filings - Apr 29 2013]
Protalix Says COFEPRIS, Public Health Institute... [Published Benzinga.com - Apr 29 2013]
UPLYSO(TM) (alfataliglicerase) Approved in Mexi... [Published GlobeNewswire: Advertising News - Apr 29 2013]
PROTALIX BIOTHERAPEUTICS INC. : UPLYSO(TM) (alf... [Published 4 Traders - Apr 29 2013]
UPLYSO(TM) (alfataliglicerase) Approved in Mexi... [Published Yahoo! Finance - Apr 29 2013]
UPLYSO(TM) (alfataliglicerase) Approved in Mexi... [Published Zecco - Apr 29 2013]
Katten Hosts North America-Israel Biotech Confe... [Published Katten Muchin Rosenman - Apr 23 2013]
Protalix BioTherapeutics Rating Lowered to Unde... [Published American Banking News - Stock Ratings - Apr 22 2013]
Protalix BioTherapeutics Treats First Gaucher P... [Published PipelineReview - Apr 13 2013]
Top 8 Best-Selling Orphan Drugs Approved and La... [Published Terrapinn - Apr 12 2013]
8-K - Protalix BioTherapeutics, Inc. (000100628... [Published SEC Filings - Apr 02 2013]
Protalix BioTherapeutics Treats First Gaucher P... [Published GlobeNewswire: Acquisitions News - Apr 02 2013]
4 Healthcare Stock Stories for Tuesday Investme... [Published Wall St. Cheat Sheet - Mar 19 2013]
U.S. Food and Drug Administration Approved 30% ... [Published Marketwire - Breaking News Releases - Mar 19 2013]

Blogs

sort by: Date \| Relevance
J.C. Penney Lands a Loan, Protalix Rides on App... [Published Wall St. Cheat Sheet - Apr 29 2013] J.C. Penney ( NYSE:JCP ): It appears that all the shuffling and negotiating has paid off, as the retailer was able to land $1.75 billion in loans with a five-year structure that uses its real estate holdings as collateral. Outstanding debt will now be ...
J.C. Penney Lands a Loan, Protalix Rides on App... [Published Wall St. Cheat Sheet - Apr 29 2013] J.C. Penney ( NYSE:JCP ): It appears that all the shuffling and negotiating has paid off, as the retailer was able to land $1.75 billion in loans with a five-year structure that uses its real estate holdings as collateral. Outstanding debt will now ...
4 Healthcare Stock Stories for Tuesday Investme... [Published Wall St. Cheat Sheet - Mar 19 2013] Affymax ( NASDAQ:AFFY ): Current price $1.09 Late Monday, the company announced that it will slash its workforce as part of a plan to concentrate its resources on the ongoing inquiry of reported hypersensitivity reactions in patients receiving Omontys ...
Pfizer, Protalix type I Gaucher disease drug Up... [Published PBR - News - Mar 19 2013] Pfizer and Protalix BioTherapeutics have obtained approval from the Brazilian National Health Surveillance Agency for Uplyso (alfataliglicerase) as type I Gaucher disease therapy. ...
2 Top Stories Affecting Dow 30 Healthcare Stock... [Published Wall St. Cheat Sheet - Feb 11 2013] Pfizer ( NYSE:PFE ): Current price $26.85 Shares of the Israeli pharmaceutical firm Protalix BioTherapeutics ( AMEX:PLX ) have taken off, following the website Calcalist reporting that the company is in discussions to be purchased for $1 billion. ...

Press Releases

sort by: Date \| Relevance
Protalix BioTherapeutics to Present at the Oppe... [Published GlobeNewswire: Acquisitions News - May 08 2013]
UPLYSO(TM) (alfataliglicerase) Approved in Mexi... [Published GlobeNewswire: Advertising News - Apr 29 2013]
Protalix BioTherapeutics Treats First Gaucher P... [Published GlobeNewswire: Acquisitions News - Apr 02 2013]
U.S. Food and Drug Administration Approved 30% ... [Published Marketwire - Breaking News Releases - Mar 19 2013]
UPLYSO(TM) (alfataliglicerase) Approved in Braz... [Published GlobeNewswire: Acquisitions News - Mar 18 2013]